Profile data is unavailable for this security.
About the company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
- Revenue in USD (TTM)22.32bn
- Net income in USD4.64bn
- Incorporated1901
- Employees33.63k
- LocationEli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
- Phone+1 (317) 276-2000
- Fax+1 (317) 276-3492
- Websitehttps://www.lilly.com/
Mergers & acquisitions
| Acquired company | LLY:NYQ since announced | Transaction value |
|---|---|---|
| Dermira Inc | 4.50% | 1.04bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 22.45bn | 5.39bn | 88.18bn | 11.00k | 16.56 | 3.90 | 23.65 | 3.93 | 4.21 | 4.21 | 17.61 | 17.89 | 0.3583 | 3.25 | 6.50 | -- | 8.56 | 18.07 | 10.24 | 21.88 | 79.18 | 83.42 | 23.89 | 39.31 | 3.01 | 5.60 | -- | 24.87 | 1.46 | -2.04 | -1.34 | -14.95 | -- | -- |
| Amgen, Inc. | 23.36bn | 7.84bn | 131.40bn | 23.40k | 17.30 | 13.62 | 13.08 | 5.62 | 12.88 | 12.88 | 38.38 | 16.36 | 0.3705 | 1.34 | 6.12 | 998,376.10 | 12.44 | 10.83 | 15.72 | 12.67 | 81.35 | 81.75 | 33.57 | 34.01 | 1.16 | 18.05 | 0.7556 | 41.54 | -1.62 | 3.09 | -6.58 | 8.74 | -9.23 | 18.91 |
| Eli Lilly And Co | 22.32bn | 4.64bn | 135.84bn | 33.63k | 28.38 | 52.17 | 23.14 | 6.09 | 5.00 | 8.74 | 23.85 | 2.72 | 0.5366 | 1.50 | 4.32 | 663,776.90 | 11.15 | 8.76 | 15.89 | 12.28 | 78.85 | 76.62 | 20.78 | 16.77 | 0.8933 | 18.80 | 0.8502 | 64.42 | 3.84 | 2.62 | 39.45 | 14.17 | -2.87 | 5.65 |
| AbbVie Inc | 32.87bn | 3.32bn | 140.43bn | 30.00k | 42.52 | -- | 26.51 | 4.27 | 2.23 | 2.18 | 22.17 | -5.56 | 0.5233 | 4.07 | 5.81 | 1,095,567.00 | 5.32 | 9.30 | 7.21 | 12.12 | 77.01 | 77.24 | 10.17 | 18.82 | 1.04 | 9.45 | 1.27 | 83.76 | 16.08 | 11.75 | 1.06 | 6.83 | 5.38 | 17.54 |
| Bristol-Myers Squibb Co | 26.15bn | 3.44bn | 153.85bn | 23.30k | 29.88 | -- | 30.20 | 5.88 | 2.20 | 2.20 | 15.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 69.93 | 72.52 | 13.23 | 17.51 | -- | 95.86 | -- | -- | 15.89 | 10.49 | -30.89 | 11.41 | -- | 2.64 |
| Pfizer Inc. | 51.75bn | 16.27bn | 197.68bn | 92.40k | 12.48 | -- | 9.00 | 3.82 | 2.86 | 2.86 | 9.16 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 80.65 | 79.40 | 31.50 | 20.35 | -- | 14.90 | -- | -- | -3.54 | 0.8503 | 57.25 | 12.36 | -- | 6.72 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2019 | 69.42m | 7.23% |
| Wellington Management Co. LLPas of 31 Dec 2019 | 44.35m | 4.62% |
| PRIMECAP Management Co.as of 31 Dec 2019 | 43.12m | 4.49% |
| BlackRock Fund Advisorsas of 31 Dec 2019 | 42.77m | 4.45% |
| SSgA Funds Management, Inc.as of 31 Dec 2019 | 37.17m | 3.87% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2019 | 26.06m | 2.71% |
| State Farm Investment Management Corp.as of 31 Dec 2019 | 18.62m | 1.94% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2019 | 12.92m | 1.35% |
| Geode Capital Management LLCas of 31 Dec 2019 | 12.38m | 1.29% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2019 | 10.93m | 1.14% |
